Search results
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant.
- SYNTap® Test
SYNTap® Test - Amprion's SYNTap Test - Diagnostic Test For...
- Collaborations
To improve patient access to the SYNTap® Biomarker CSF Test,...
- Amprion News
Amprion News - Amprion's SYNTap Test - Diagnostic Test For...
- FAQ
The SYNTap Biomarker CSF Test aids physicians in diagnosing...
- References
References - Amprion's SYNTap Test - Diagnostic Test For LBD...
- Sample Reports
Sample Reports - Amprion's SYNTap Test - Diagnostic Test For...
- SYNTap® Test
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant.
Oct 5, 2021 · Amprion announces breakthrough SYNTap Biomarker Test to help physicians diagnose Alzheimer’s Disease (AD), Parkinson’s Disease (PD) & Lewy Body Dementia (LBD).
People also ask
Who is Amprion?
Does Amprion have CLIA approval?
What is Amprion biomarker testing?
What is the Amprion molecular test?
May 22, 2019 · San Francisco, California—Amprion announced its proprietary technology, Protein Misfolding Cyclic Amplification (PMCA), using CSF and plasma alpha-Synuclein (αS) to aid in the diagnosis of PD, received a Breakthrough Device designation from U.S. FDA.
Amprion is a transmission system operator in Germany. Our 11,000-kilometre extra-high voltage grid transports electricity in an area from the North Sea to the Alps.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant.
